Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 162 participants.

Also called NCT01649466

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 162 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01649466
  • EudraCT 2012-001143-46
Other papers using this trial's data
  • Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study Current medical research and opinion, 2015-06 DOI, PubMed 25867771

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01649466. Randomized; no masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.
Acronym
BENEFIT
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
LAF237
Intervention (Drug)
Protaphane
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01649466
Content hash
f8fa0933af1043242dbad871586fcfb8da328c8c8ae8e849d724ecc8ef9753eb